How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

720 results for

Panniculitis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

581. European Guidelines for Photodermatoses - Photoaggravated Disorders

+ Discoid lupus Vacuolar degeneration thickening PV PAD +/- 20% positive 20% ana/Ro positive Lupus profundus normal PV PAD panniculitis negative Positive or negative Positive or negative Rowell’s Vacuolar change- necrosis of epidermis PV negative May be + Ro & ANA may be positive SLE variable Variable variable positive positive Table 2 Level of evidence Type of evidence 1 ++ High-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias 1 + Well-conducted meta-analyses

2005 European Dermatology Forum

582. Guidelines for the management of primary cutaneous T-cell lympohomas

. When disease is restricted to the skin radio- therapy may be indicated, but systemic dissemination is likely and most patients will require some form of multiagent chemotherapy, although responses are likely to be poor. Primary cutaneous extranodal NK-like/ T-cell lymphomas (nasal type) have a poor prognosis. 2 Primary subcutaneous panniculitis-like T-cell lymphomas are rare but also have a poor prognosis with a high incidence of systemic involve- ment and haemophagocytosis either at diagnosis

2003 British Association of Dermatologists

583. Narrative review: diseases that masquerade as infectious cellulitis. (Abstract)

, familial Mediterranean fever, and foreign-body reactions. Diseases that uncommonly masquerade as infectious cellulitis include urticaria, lymphedema, lupus erythematosus, sarcoidosis, lymphoma, leukemia, Paget disease, and panniculitis. Clinicians should do an initial diagnostic work-up directed by the findings from a detailed history and complete physical examination. In many cases, skin biopsy is the only tool that helps identify the correct diagnosis. Special tests may also be needed.

2005 Annals of Internal Medicine

584. Alpha-1 antitrypsin deficiency

panniculitis. ORPHA:60 Classification level: Disorder Synonym(s): - Prevalence: 1-5 / 10 000 Inheritance: Autosomal recessive Age of onset: All ages ICD-10: E88.0 OMIM: UMLS: C0221757 C3501835 MeSH: C531610 D019896 GARD: MedDRA: 10001806 Detailed information Article for general public Professionals Summary information Emergency guidelines Review article Guidance for genetic testing Clinical genetics review Additional information Further information on this disease Health care resources for this disease

2005 Orphanet

585. Cutaneous lymphoma

T-cell lymphoma), forms with a poor prognosis (Sezary syndrome and peripheral T-cell lymphoma) and forms with a variable prognosis (pleomorphic small/medium-sized T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, cutaneous T/NK cell lymphomas (referred to as nasal-type lesions), epidermotropic CD8+ T-cell lymphomas and the TCRgamma-delta phenotype). The group of cutaneous B-cell lymphomas includes marginal zone B-cell lymphomas and primary cutaneous follicular lymphomas (both

2005 Orphanet

586. Lupus erythematosus, cutaneous

, tinea corporis, erythema anulare centrifugum, granuloma annulare, erythema gyratum repens, psoriasis. DLE: sarcoidosis, tuberculosis, leprosy, classic mycosis fungoides, cutaneous pseudolymphoma, granuloma faciale, nummular eczema, psoriasis, squamous and basal cell carcinoma, rosacea, lichen planus. ChLE: frostbites. LEP: subcutaneous panniculitis-like T-cell lymphoma, erythema nodosum. LET: Jessner lymphocytic infiltration of the skin, polymorphous light eruption, reticular erythematosus mucinosis

2005 Orphanet

587. Feasibility Study of a Novel Device for Chronic Wounds

site. However, wounds that are closing by secondary intent after surgical clearance of prior tumor will be allowed in the study. Thick eschar at wound base after debridement. Wound location is not amenable to forming an airtight seal and placement of device. Ulcers due to inflammatory conditions such as pyoderma gangrenosum, rheumatoid arthritis, vasculitis, cryoglobulinemia, necrobiosis lipoidica diabeticorum, lupus or pancreatic panniculitis, cryofibrinogenemia, calcinosis cutis, scleroderma

2008 Clinical Trials

588. A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT

Angioimmunoblastic T-cell lymphoma NK/T nasal-type T-cell lymphoma Enteropathy-type T-cell lymphoma Primary systemic, alk-negative anaplastic large cell lymphoma (T-or null phenotype) Hepatosplenic T-cell lymphoma Subcutaneous panniculitis-like T-cell lymphoma NB: Patients should not enter the treatment program before confirmation of the histo-pathological diagnosis by the referral center pathologist Age 18-60 years. Patients in the age range 61-67 years may be included in this protocol at discretion

2008 Clinical Trials

589. 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer

Extranodal NK/T cell lymphoma (nasal and nasal type) Enteropathy-type T-cell lymphoma Hepatosplenic T-cell lymphoma Angioimmunoblastic T-cell lymphoma Subcutaneous panniculitis-like T-cell lymphoma Chronic lymphocytic leukemia (CLL) Patients with NHL or CLL must meet the following criteria: Ineligible for, or refused potentially curative stem cell transplantation Transformed lymphoma/Richter's transformation, defined as the transformation of low-grade lymphoma, including follicular lymphoma, CLL

2005 Clinical Trials

590. UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas

systemic Anaplastic Large Cell Lymphoma (ALCL). Relapsed or refractory mature T-cell lymphoma to include peripheral T-cell lymphoma unspecified and the following "specified" mature T-cell lymphomas: Adult T-cell lymphoma; Extranodal natural killer (NK)/T-cell lymphoma, nasal type; Enteropathy-type T-cell lymphoma; Hepatosplenic T-cell lymphoma; Subcutaneous panniculitis-like T-cell lymphoma; Angioimmunoblastic T-cell lymphoma. All patients should have evaluable or measurable disease on entry to study

2004 Clinical Trials

591. S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma

Subcutaneous panniculitis-like T-cell lymphoma Angioimmunoblastic T-cell lymphoma Primary cutaneous anaplastic large cell lymphoma (ALCL) ALCL with CD30, ALK, and EMA expression ALCL morphology that fails to express ALK or EMA allowed provided T-cell lineage is confirmed by immunotyping or genetic testing Bidimensionally measurable disease Adequate samples (e.g., core biopsies, especially multiple core biopsies) from the original diagnostic specimen available Needle aspiration or cytology is not considered

2005 Clinical Trials

592. Alemtuzumab and CHOP in T-cell Lymphoma

Enteropathy-type T cell lymphoma Subcutaneous panniculitis-like T-NHL (gamma-delta T-cell lymphoma) Hepatosplenic T-cell lymphoma Extranodal NK/T cell lymphoma, nasal type Age 18-60 years at time of randomization Life expectancy of 3 months or longer ECOG performance status (PS) 0, 1 or 2 at the time of randomization. However, PS 3 will be acceptable if lymphoma-related. Measurable disease (defined as at least one lesion with two measurable perpendicular diameters of which at least one should be >= 15 mm

2008 Clinical Trials

593. Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

: Peripheral T-cell lymphoma not otherwise specified (PTCL-U),(IPI >2) Angioimmunoblastic T-cell lymphoma (IPI >2) Non-primary cutaneous Alk-1-negative anaplastic large cell lymphoma Extranodal NK/T lymphoma (Excluding stage I/II nasal disease) Blastic NK cell lymphoma Enteropathy type T-cell lymphoma Subcutaneous panniculitis-like T-cell lymphoma Hepatosplenic T-cell lymphoma Measurable or assessable disease is not required. Age >18 and < 70 years Previously untreated or 1 prior cycle of chemotherapy

2008 Clinical Trials

594. Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas

in the relapsed and/or refractory setting following prior anthracycline therapy. Subtypes of peripheral T-cell lymphomas which meet this criteria will include the following: adult T-cell leukemia/lymphoma, peripheral T-cell lymphoma unspecified, angioimmunoblastic T-cell lymphoma, anaplastic large-cell lymphoma, T/null cell, primary systemic type, subcutaneous panniculitis-like T-cell lymphoma, hepatosplenic gamma-delta T-cell lymphoma, and enteropathy-type T-cell lymphoma [33]. Patients with a history

2008 Clinical Trials

595. Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma

lymphoma (DLBCL) is allowed if the patient is not eligible for, or refuses, hematopoetic stem cell transplant. Relapsed/refractory nodal, leukemic, and extranodal T cell lymphomas are eligible. Subtypes eligible include anaplastic large cell lymphoma, angioimmunoblastic T cell lymphoma, PTCL-NOS, nasal or disseminated extranodal T/NK lymphoma, enteropathy-associated T cell lymphoma, hepatosplenic gamma/delta T cell lymphoma, subcutaneous panniculitis-like T cell lymphoma, T-prolymphocytic leukemia (...) B and T cell cutaneous lymphoma relapsed or refractory diffuse large B cell lymphoma extranodal T cell lymphomas anaplastic large cell lymphoma angioimmunoblastic T cell lymphoma PTCL-NOS nasal or disseminated extranodal T/NK lymphoma enteropathy-associated T cell lymphoma hepatosplenic gamma/delta T cell lymphoma subcutaneous panniculitis-like T cell lymphoma T-prolymphocytic leukemia adult T-cell leukemia/lymphoma large granular lymphocytic leukemia aggressive NK leukemia Additional relevant

2008 Clinical Trials

596. The Use of High Resolution Chest Computed Tomography in Alpha-1 Antitrypsin Deficiency

long-term or acute inflammation outside the lung, including connective diseases, panniculitis, or acute infection Unwilling to alter bronchodilator medications for 24 hours prior to scheduled quantitative CT (QCT) scans Musculoskeletal disease that limits exercise by walking Required to take any of the following medications within 48 hours of scheduled lung function testing: dicyclomine (Bentyl), propantheline (Pro-Banthine), mepenzolate (Cantil), methscopolamine (Pamine), and scopolamine

2007 Clinical Trials

597. Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies

, Inc: Lymphoproliferative malignancies Lymphoma Hodgkin's lymphoma (HL) Non-Hodgkin's lymphoma (NHL) PTCL T/NK-cell leukemia/lymphoma T-cell lymphoma/leukemia (HTLV 1+) Angioimmunoblastic T-cell lymphoma Blastic NK lymphoma Anaplastic large cell lymphoma T/NK-cell lymphoma Enteropathy-type intestinal lymphoma Hepatosplenic T-cell lymphoma Extranodal peripheral T/NK-cell lymphoma Subcutaneous panniculitis T-cell lymphoma Transformed mycosis fungoides PDX Pralatrexate Gemcitabine Gemzar Vitamin B12

2007 Clinical Trials

598. The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL

Subcutaneous panniculitis-like T-cell lymphoma Anaplastic large-cell lymphoma,T/null cell,primary systemic type Peripheral T-cell lymphoma,not otherwise characterized Newly diagnosed,age 15-65 years. Complete work up for baseline evaluation and measurement (Appendix B) Patient's free written inform consent. Exclusion Criteria: Patients with a known hypersensitivity to murine proteins or to any component of alemtuzumab. Patients who have received prior antilymphoma treatment with chemotherapy

2007 Clinical Trials

599. Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment

fungoides Subcutaneous panniculitis-like T-cell lymphoma Nasal T/NK-cell lymphoma Enteropathy-type T-cell lymphoma Hepatosplenic gamma/delta T-cell lymphoma Relapsed or refractory disease, meeting both of the following criteria: Must have been treated with prior cytotoxic chemotherapy and/or monoclonal antibody therapy No standard curative treatment exists Allogeneic bone marrow transplantation is not considered standard curative treatment Evaluable disease (Phase I) Measurable disease, defined as any

2006 Clinical Trials

600. Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment

macroglobulinemia) Central Nervous System (CNS) lymphoma Post-transplant lymphoproliferative disorder Mycosis fungoides/Sezary syndrome Hodgkin's lymphoma Primary effusion lymphoma Blastic Natural Killer(NK)-cell lymphoma Adult T-cell leukemia/lymphoma Nasal type extranodal NK/T-cell lymphoma Enteropathy type T-cell lymphoma Hepatosplenic T-cell lymphoma Subcutaneous panniculitis-like T-cell lymphoma Angioimmunoblastic T-cell lymphoma NOTE: *Biopsies performed < 6 months prior to study entry are allowed; biopsy

2007 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>